

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 December 2024 (26.12.2024)



(10) International Publication Number
WO 2024/263852 A2

- (51) International Patent Classification:
C12N 15/11 (2006.01) A61K 31/712 (2006.01)
- (21) International Application Number:
PCT/US2024/034923
- (22) International Filing Date:
21 June 2024 (21.06.2024)

- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
63/509,696 22 June 2023 (22.06.2023) US

- (71) Applicant: **DENALI THERAPEUTICS INC.** [US/US];
161 Oyster Point Boulevard, South San Francisco, California 94080 (US).

- (72) Inventors: **BARKER, Scarlett**; c/o Denali Therapeutics Inc., 161 Oyster Point Boulevard, South San Francisco, California 94080 (US). **DEVOS, Sarah L.**; c/o Denali Therapeutics Inc., 161 Oyster Point Boulevard, South San Francisco, California 94080 (US). **THAYER, Mai B.**; c/o Denali Therapeutics Inc., 161 Oyster Point Boulevard, South San Francisco, California 94080 (US). **KLAR, Richard**; c/o Denali Therapeutics Inc., 161 Oyster Point Boulevard, South San Francisco, California 94080 (US). **MICHEL, Sven**; c/o Denali Therapeutics Inc., 161 Oyster Point Boulevard, South San Francisco, California 94080 (US). **JASCHINSKI, Frank**; c/o Denali Therapeutics Inc., 161 Oyster Point Boulevard, South San Francisco, California 94080 (US). **ROTHKIRCH, Larissa**; c/o Denali Therapeutics Inc., 161 Oyster Point Boulevard, South San Francisco, California 94080 (US).

- (74) Agent: **EKENA, Kirk** et al.; Alston & Bird LLP, Vantage South End, 1120 South Tryon Street, Suite 300, Charlotte, North Carolina 28203-6818 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

WO 2024/263852 A2

- (54) Title: COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION

- (57) Abstract: Provided herein are MAPT antisense oligonucleotides that are capable of modulating the expression of a MAPT target nucleic acid. Also provided herein are methods of use thereof.